Peritoneal carcinomatosis from adenocarcinoma of the colon
- PMID: 8661635
- DOI: 10.1007/s002689900091
Peritoneal carcinomatosis from adenocarcinoma of the colon
Abstract
Peritoneal carcinomatosis is a major cause of surgical treatment failure in patients with colorectal cancer. In the past patients with this condition have had a lethal outcome. In this study, 64 consecutive patients were treated by the cytoreductive approach, which involved surgery to maximally resect all cancer in the abdomen and pelvis, early postoperative intraperitoneal chemotherapy with 5-fluorouracil (5-FU) and mitomycin C, and three cycles of adjuvant intraperitoneal 5-FU with systemic mitomycin C. The clinical features that may affect prognosis were assessed and critically analyzed statistically. Peritoneal implant size of < 5 cm present in the abdomen and pelvis at the time of exploration correlated with a good prognosis (p < 0.0001), as did complete cytoreduction with tumor removed to nodules < 2.5 mm (p < 0.0001). Involvement of only one or two of the five abdominopelvic regions, compared to three or more regions, was a significant determinant of prognosis (p < 0.0001). Finally, a mucinous histologic type correlated adversely with prognosis when compared to intestinal-type adenocarcinomas (p < 0.001). These data suggest that patients with small-volume peritoneal seeding from colon cancer should be treated with cytoreductive surgery and aggressive regional and systemic chemotherapy in an attempt to achieve long-term disease-free survival.
Similar articles
-
Peritoneal carcinomatosis from adenocarcinoma of the colon.Cancer Treat Res. 1996;81:247-60. doi: 10.1007/978-1-4613-1245-1_21. Cancer Treat Res. 1996. PMID: 8834590
-
Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.Dis Colon Rectum. 2000 Oct;43(10):1341-6; discussion 1347-8. doi: 10.1007/BF02236627. Dis Colon Rectum. 2000. PMID: 11052509 Clinical Trial.
-
Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.In Vivo. 2010 Jan-Feb;24(1):79-84. In Vivo. 2010. PMID: 20133981
-
New responsibilities in the management of colorectal cancer with peritoneal seeding.Cancer Invest. 2002;20(7-8):1118-22. doi: 10.1081/cnv-120005929. Cancer Invest. 2002. PMID: 12449746 Review.
-
Current status and future directions: management of colon cancer with peritoneal dissemination.Future Oncol. 2008 Oct;4(5):671-9. doi: 10.2217/14796694.4.5.671. Future Oncol. 2008. PMID: 18922124 Review.
Cited by
-
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.Br J Cancer. 2004 Jan 26;90(2):403-7. doi: 10.1038/sj.bjc.6601586. Br J Cancer. 2004. PMID: 14735184 Free PMC article. Clinical Trial.
-
Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases.Langenbecks Arch Surg. 2019 Aug;404(5):527-539. doi: 10.1007/s00423-019-01805-x. Epub 2019 Aug 3. Langenbecks Arch Surg. 2019. PMID: 31377856
-
The Landmark Series: Surgical Treatment of Colorectal Cancer Peritoneal Metastases.Ann Surg Oncol. 2021 Aug;28(8):4140-4150. doi: 10.1245/s10434-021-10049-3. Epub 2021 May 9. Ann Surg Oncol. 2021. PMID: 33969466 Review.
-
Cytoreductive surgery and intraoperative intraperitoneal hyperthermic chemotherapy in patients with peritoneal carcinomatosis of colorectal origin.Clin Transl Oncol. 2005 Nov;7(10):421-31. doi: 10.1007/BF02716592. Clin Transl Oncol. 2005. PMID: 16373050 Review.
-
Treatment recommendations for metastatic colorectal cancer.Clin Transl Oncol. 2011 Mar;13(3):162-78. doi: 10.1007/s12094-011-0636-7. Clin Transl Oncol. 2011. PMID: 21421461 Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous